Objective: This study aimed to evaluate the clinical relevance of early relative dose intensity (eRDI) during enfortumab vedotin (EV) monotherapy in patients with metastatic urothelial carcinoma (mUC) based on a Japanese real‐world multicenter cohort. Methods: We retrospectively analyzed 119 patients with mUC who received EV. The temporal trend of total relative dose intensity (tRDI), defined as the cumulative relative dose intensity during treatment, was assessed over the first 5 months. eRDI, calculated as the mean RDI over the initial 3 months, was also evaluated. Survival analyses were performed in 84 patients evaluable beyond the first radiographic assessment, excluding those with early progressive disease (PD). Patients were stratified by eRDI (≥ 80% vs. < 80%), and progression‐free survival (PFS) and overall survival (OS) were compared. Subgroup analyses were conducted according to the presence or absence of adverse event–related dose modification (AE‐related DM). Results: Dose intensity gradually declined during the early treatment phase. The eRDI was not significantly associated with PFS or OS in the PD‐excluded cohort ( n = 84). However, among patients without AE‐related DM ( n = 44), high eRDI was associated with significantly longer PFS (median 11.7 vs. 4.2 months; p = 0.001) and OS (not reached vs. 13.8 months; p = 0.021). No significant association was observed between eRDI and survival in patients with AE‐related DM. Conclusions: Although eRDI was not an overall significant prognostic factor, it showed clinical relevance in patients without AE‐related DM. These findings underscore the importance of preserving eRDI in patients with sufficient tolerability and support individualized dosing strategies for EV therapy.
Introduction: Peritoneal carcinomatosis in patients with advanced bladder cancer is a rare but lethal event following robot‐assisted radical cystectomy (RARC). We report a case of an unusual clinical course in which peritoneal dissemination of colon cancer was unexpectedly detected seven months after RARC. Case Presentation: A 67‐year‐old man underwent two courses of neoadjuvant chemotherapy and subsequent RARC with extracorporeal urinary diversion for muscle‐invasive bladder cancer. The pathological diagnosis of the RARC specimen was urothelial carcinoma in situ (ypTis). After 7 months, the patient developed small bowel obstruction and underwent laparotomy. Intraoperatively, numerous seeding nodules were observed in the pelvic cavities, involving the small intestine. Contrary to our expectation of bladder cancer recurrence, the pathological examination revealed adenocarcinoma, suggesting primary colorectal cancer. Conclusion: Peritoneal dissemination occurring shortly after RARC is often considered due to bladder cancer. However, the possibility of metastasis from other cancers must be taken into consideration.